Immuneering Co. (NASDAQ:IMRX) Receives $12.60 Consensus Target Price from Analysts

Immuneering Co. (NASDAQ:IMRX) has been assigned an average recommendation of “Moderate Buy” from the seven analysts that are covering the stock, MarketBeat reports. Three equities research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $12.60.

Several equities analysts have commented on IMRX shares. Needham & Company LLC reissued a “buy” rating and issued a $15.00 price target on shares of Immuneering in a research report on Friday, September 13th. Chardan Capital cut their price target on Immuneering from $16.00 to $12.00 and set a “buy” rating on the stock in a report on Wednesday, August 7th.

Institutional Trading of Immuneering

A number of institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. lifted its stake in Immuneering by 12.1% during the first quarter. Vanguard Group Inc. now owns 1,203,666 shares of the company’s stock worth $3,479,000 after purchasing an additional 129,851 shares during the last quarter. Acadian Asset Management LLC purchased a new stake in shares of Immuneering during the 2nd quarter worth approximately $67,000. Renaissance Technologies LLC acquired a new position in shares of Immuneering in the 2nd quarter valued at $447,000. XTX Topco Ltd grew its position in shares of Immuneering by 37.3% in the 2nd quarter. XTX Topco Ltd now owns 34,159 shares of the company’s stock valued at $44,000 after buying an additional 9,274 shares during the last quarter. Finally, Marshall Wace LLP acquired a new stake in Immuneering during the 2nd quarter worth $492,000. 67.65% of the stock is owned by hedge funds and other institutional investors.

Immuneering Stock Performance

Immuneering stock opened at $1.87 on Friday. The company has a market capitalization of $55.45 million, a PE ratio of -0.98 and a beta of -0.45. Immuneering has a fifty-two week low of $1.00 and a fifty-two week high of $8.89. The firm has a 50 day moving average price of $2.02 and a 200 day moving average price of $1.59.

Immuneering (NASDAQ:IMRX) last announced its earnings results on Tuesday, August 6th. The company reported ($0.47) EPS for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.05. As a group, equities research analysts forecast that Immuneering will post -1.89 earnings per share for the current year.

Immuneering Company Profile

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.